Dynamic Biosensors

Executive Summary

Dynamic Biosensors is a German diagnostics and proteomics company headquartered in Munich, founded in 2012. The company has developed a proprietary biosensor platform, switchSENSE®, which enables real-time, label-free analysis of molecular interactions, including binding kinetics, concentration, and size measurements. This technology addresses a critical need in drug discovery and life sciences research, where understanding molecular mechanisms is essential for developing new therapies for diseases such as cancer. By providing high-resolution biophysical data without the need for fluorescent labels, Dynamic Biosensors aims to accelerate the drug development pipeline and reduce costs. The platform is already used by academic and pharmaceutical researchers globally, positioning the company as a key player in the growing markets of proteomics and diagnostics. Dynamic Biosensors operates in a competitive landscape but differentiates itself through its unique electro-switchable DNA nanolever technology, which offers superior sensitivity and throughput compared to traditional methods like SPR and ITC. With increasing demand for advanced biophysical characterization tools, the company is well-positioned for growth. While financial details remain undisclosed as a private entity, the company's focus on precision medicine and its established commercial presence suggest a strong trajectory. Ongoing R&D efforts are likely to expand the platform's applications into areas such as point-of-care diagnostics and personalized medicine, further strengthening its market position.

Upcoming Catalysts (preview)

• Q4 2026Launch of Next-Generation switchSENSE® Platform with Enhanced Throughput70% success
• Q3 2026Series B Funding Round to Scale Manufacturing and Sales60% success
• Q2 2026Strategic Partnership with Top-20 Pharma Company for Drug Discovery Applications50% success